Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
September 30, 2024 01:00 ET
|
Addex Therapeutics
Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophreniaIndivior selected GABA B PAM drug candidate for development in substance use disordersAddex...
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
September 19, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric...
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
August 27, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio...
Addex’s Partner Discontinues ADX71149 development in Epilepsy
July 22, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio...
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
July 15, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
July 12, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric...
Addex Shareholders Approve All Resolutions at Annual General Meeting
July 01, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
June 06, 2024 01:00 ET
|
Addex Therapeutics
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 -...
Addex Convenes Annual General Meeting 2024
June 05, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...